Analysts Set Zynex, Inc. (NASDAQ:ZYXI) Price Target at $14.88

Zynex, Inc. (NASDAQ:ZYXIGet Rating) has been assigned a consensus recommendation of “Buy” from the six research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $14.88.

A number of research analysts have recently issued reports on ZYXI shares. B. Riley dropped their price target on shares of Zynex from $15.50 to $10.00 and set a “buy” rating on the stock in a research report on Monday, February 28th. Piper Sandler lowered their price objective on Zynex from $13.00 to $7.00 in a research report on Friday, February 25th. Zacks Investment Research lowered Zynex from a “hold” rating to a “sell” rating in a research note on Saturday, April 30th. Finally, HC Wainwright reduced their price objective on shares of Zynex from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, February 25th.

NASDAQ:ZYXI traded up $0.35 during mid-day trading on Friday, reaching $7.56. 305,979 shares of the company were exchanged, compared to its average volume of 415,745. The company has a quick ratio of 3.07, a current ratio of 3.67 and a debt-to-equity ratio of 0.13. Zynex has a 12 month low of $4.97 and a 12 month high of $16.26. The stock has a market cap of $295.19 million, a PE ratio of 15.52 and a beta of 0.87. The company has a fifty day moving average of $6.67 and a 200 day moving average of $8.27.

Zynex (NASDAQ:ZYXIGet Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.04. The company had revenue of $40.37 million for the quarter, compared to analyst estimates of $41.06 million. Zynex had a return on equity of 28.38% and a net margin of 13.98%. On average, equities research analysts anticipate that Zynex will post 0.44 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. boosted its position in shares of Zynex by 12.7% during the first quarter. BlackRock Inc. now owns 3,419,912 shares of the company’s stock valued at $21,307,000 after buying an additional 384,548 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Zynex by 8.0% during the first quarter. Vanguard Group Inc. now owns 1,414,853 shares of the company’s stock valued at $8,815,000 after buying an additional 104,476 shares during the last quarter. State Street Corp boosted its position in shares of Zynex by 13.4% during the first quarter. State Street Corp now owns 675,626 shares of the company’s stock valued at $4,209,000 after buying an additional 80,084 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Zynex by 1,919.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 545,960 shares of the company’s stock valued at $5,443,000 after buying an additional 518,927 shares during the last quarter. Finally, Millennium Management LLC boosted its position in shares of Zynex by 12.8% during the fourth quarter. Millennium Management LLC now owns 381,632 shares of the company’s stock valued at $3,805,000 after buying an additional 43,226 shares during the last quarter. 28.06% of the stock is owned by hedge funds and other institutional investors.

About Zynex (Get Rating)

Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device.

Featured Stories

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.